245 related articles for article (PubMed ID: 25894871)
1. Oligonucleotide therapies: the future of amyotrophic lateral sclerosis treatment?
Aoki Y; Douglas AG; Wood MJ
Neurodegener Dis Manag; 2015; 5(2):93-5. PubMed ID: 25894871
[No Abstract] [Full Text] [Related]
2. C9orf72 amyotrophic lateral sclerosis and frontotemporal dementia: gain or loss of function?
Mizielinska S; Isaacs AM
Curr Opin Neurol; 2014 Oct; 27(5):515-23. PubMed ID: 25188012
[TBL] [Abstract][Full Text] [Related]
3. Amyotrophic lateral sclerosis and gene therapy.
Miller TM; Smith RA; Cleveland DW
Nat Clin Pract Neurol; 2006 Sep; 2(9):462-3. PubMed ID: 16932606
[No Abstract] [Full Text] [Related]
4. Tofersen: First Approval.
Blair HA
Drugs; 2023 Jul; 83(11):1039-1043. PubMed ID: 37316681
[TBL] [Abstract][Full Text] [Related]
5. Effect of Mutations in SOD1 and C9orf72 Genes on Autophagy in Lymphomonocytes in Myotrophic Lateral Sclerosis.
Kochergin IA; Shpilyukova YA; Lysogorskaia EV; Abramycheva NY; Zakharova MN; Illarioshkin SN
Bull Exp Biol Med; 2019 Sep; 167(5):667-670. PubMed ID: 31625064
[TBL] [Abstract][Full Text] [Related]
6. Experimental therapies hold promise for treating amyotrophic lateral sclerosis.
Friedrich MJ
JAMA; 2005 Mar; 293(9):1048-9. PubMed ID: 15741517
[No Abstract] [Full Text] [Related]
7. [Gene-specific treatment approaches in amyotrophic lateral sclerosis in the present and future].
Brenner D; Freischmidt A; Ludolph AC; Weishaupt JH
Nervenarzt; 2020 Apr; 91(4):287-293. PubMed ID: 32076756
[TBL] [Abstract][Full Text] [Related]
8. An RNAi strategy for treatment of amyotrophic lateral sclerosis caused by mutant Cu,Zn superoxide dismutase.
Xia XG; Zhou H; Zhou S; Yu Y; Wu R; Xu Z
J Neurochem; 2005 Jan; 92(2):362-7. PubMed ID: 15663483
[TBL] [Abstract][Full Text] [Related]
9. Clinical characteristics of patients with familial amyotrophic lateral sclerosis carrying the pathogenic GGGGCC hexanucleotide repeat expansion of C9ORF72.
Chiò A; Borghero G; Restagno G; Mora G; Drepper C; Traynor BJ; Sendtner M; Brunetti M; Ossola I; Calvo A; Pugliatti M; Sotgiu MA; Murru MR; Marrosu MG; Marrosu F; Marinou K; Mandrioli J; Sola P; Caponnetto C; Mancardi G; Mandich P; La Bella V; Spataro R; Conte A; Monsurrò MR; Tedeschi G; Pisano F; Bartolomei I; Salvi F; Lauria Pinter G; Simone I; Logroscino G; Gambardella A; Quattrone A; Lunetta C; Volanti P; Zollino M; Penco S; Battistini S; ; Renton AE; Majounie E; Abramzon Y; Conforti FL; Giannini F; Corbo M; Sabatelli M
Brain; 2012 Mar; 135(Pt 3):784-93. PubMed ID: 22366794
[TBL] [Abstract][Full Text] [Related]
10. Novel behavioural characteristics of the superoxide dismutase 1 G93A (SOD1
Kreilaus F; Guerra S; Masanetz R; Menne V; Yerbury J; Karl T
Genes Brain Behav; 2020 Feb; 19(2):e12604. PubMed ID: 31412164
[TBL] [Abstract][Full Text] [Related]
11. Combined fulminant frontotemporal dementia and amyotrophic lateral sclerosis associated with an I113T SOD1 mutation.
Katz JS; Katzberg HD; Woolley SC; Marklund SL; Andersen PM
Amyotroph Lateral Scler; 2012 Oct; 13(6):567-9. PubMed ID: 22670877
[TBL] [Abstract][Full Text] [Related]
12. Development of LNA Gapmer Oligonucleotide-Based Therapy for ALS/FTD Caused by the C9orf72 Repeat Expansion.
Sathyaprakash C; Manzano R; Varela MA; Hashimoto Y; Wood MJA; Talbot K; Aoki Y
Methods Mol Biol; 2020; 2176():185-208. PubMed ID: 32865792
[TBL] [Abstract][Full Text] [Related]
13. [Genetic architecture of amyotrophic lateral sclerosis and frontotemporal dementia : Overlap and differences].
Synofzik M; Otto M; Ludolph A; Weishaupt JH
Nervenarzt; 2017 Jul; 88(7):728-735. PubMed ID: 28573364
[TBL] [Abstract][Full Text] [Related]
14. RNA interference and amyotrophic lateral sclerosis.
Rizvanov AA; Gulluoglu S; Yalvaç ME; Palotás A; Islamov RR
Curr Drug Metab; 2011 Sep; 12(7):679-83. PubMed ID: 21740381
[TBL] [Abstract][Full Text] [Related]
15. RNAi therapy: dominant disease gene gets silenced.
Xu Z; Xia XG
Gene Ther; 2005 Aug; 12(15):1159-60. PubMed ID: 15858609
[No Abstract] [Full Text] [Related]
16. Current developments in gene therapy for amyotrophic lateral sclerosis.
Scarrott JM; Herranz-Martín S; Alrafiah AR; Shaw PJ; Azzouz M
Expert Opin Biol Ther; 2015 Jul; 15(7):935-47. PubMed ID: 25959569
[TBL] [Abstract][Full Text] [Related]
17. Is SOD1 loss of function involved in amyotrophic lateral sclerosis?
Saccon RA; Bunton-Stasyshyn RK; Fisher EM; Fratta P
Brain; 2013 Aug; 136(Pt 8):2342-58. PubMed ID: 23687121
[TBL] [Abstract][Full Text] [Related]
18. Selective silencing by RNAi of a dominant allele that causes amyotrophic lateral sclerosis.
Ding H; Schwarz DS; Keene A; Affar el B; Fenton L; Xia X; Shi Y; Zamore PD; Xu Z
Aging Cell; 2003 Aug; 2(4):209-17. PubMed ID: 12934714
[TBL] [Abstract][Full Text] [Related]
19. Genetic analysis of amyotrophic lateral sclerosis in the Slovenian population.
Vrabec K; Koritnik B; Leonardis L; Dolenc-Grošelj L; Zidar J; Smith B; Vance C; Shaw C; Rogelj B; Glavač D; Ravnik-Glavač M
Neurobiol Aging; 2015 Mar; 36(3):1601.e17-20. PubMed ID: 25585530
[TBL] [Abstract][Full Text] [Related]
20. Approaches to Gene Modulation Therapy for ALS.
Meijboom KE; Brown RH
Neurotherapeutics; 2022 Jul; 19(4):1159-1179. PubMed ID: 36068427
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
